Lymphoblastic lymphoma in adult patients

Clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia

C. Bernasconi, E. Brusamolino, M. Lazzarino, E. Morra, G. Pagnucco, E. Orlandi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

This paper analyzes the clinicopathological features of 31 consecutive adult patients with lymphoblastic lymphoma (LBL) and reports on our experience in treating them with two successive multidrug programs analogous to those used in acute lymphoblastic leukemia (ALL) in adults. Protocol 1 (18 patients) consisted of an intensive four-drug induction therapy (daunorubicin, cyclophosphamide, vincristine, prednisone), CNS prophylaxis (cranial irradiation and intrathecal methotrexate), and continuous maintenance with methotrexate and mercaptopurine for three years, with periodical reinductions with vincristine and prednisone. Protocol 2 (13 patients) included a similar induction regimen (doxorubicin instead of daunorubicin, dexamethasone instead of prednisone), followed by post-remission intensification with alternating courses of non-cross-resistant agents (amsacrine and high dose cytarabine; vincristine, cyclophosphamide and doxorubicin; etoposide and conventional dose cytarabine) given in a cyclical eight-month program. CNS prophylaxis consisted of intrathecal methotrexate and systemic high-dose cytarabine. The patient characteristics of the two therapy groups were comparable. The complete remission (CR) rate for both groups was 77%, with a median overall and relapse-free survival of 18 and 29 months, respectively. The three-year overall survival of complete remitters was 59%. No correlation was found between CR rate and age, mediastinal, or bone marrow involvement. Stage I disease had a significantly higher CR rate (100%) than did stages II-IV (64%). Leukemic evolution occurred in 32% of cases, within a median time of 11 months from diagnosis; meningeal disease developed in six cases (19%); in four of them leukemia was concomitant. No significant differences were found between the two successive treatments for CR rate, survival, CNS relapses or toxicity. Our overall results, comparable to those of other studies, confirm the efficacy of an ALL-like therapy in adult LBL, irrespective of clinical features, stage or bone marrow involvement at diagnosis.

Original languageEnglish
Pages (from-to)141-146
Number of pages6
JournalAnnals of Oncology
Volume1
Issue number2
Publication statusPublished - 1990

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytarabine
Vincristine
Prednisone
Methotrexate
Drug Therapy
Daunorubicin
Doxorubicin
Cyclophosphamide
Bone Marrow
Amsacrine
Cranial Irradiation
Recurrence
6-Mercaptopurine
Survival
Etoposide
Group Psychotherapy
Dexamethasone
Leukemia
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lymphoblastic lymphoma in adult patients : Clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia. / Bernasconi, C.; Brusamolino, E.; Lazzarino, M.; Morra, E.; Pagnucco, G.; Orlandi, E.

In: Annals of Oncology, Vol. 1, No. 2, 1990, p. 141-146.

Research output: Contribution to journalArticle

@article{9e40989a62234ea28f0514822ccad7ae,
title = "Lymphoblastic lymphoma in adult patients: Clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia",
abstract = "This paper analyzes the clinicopathological features of 31 consecutive adult patients with lymphoblastic lymphoma (LBL) and reports on our experience in treating them with two successive multidrug programs analogous to those used in acute lymphoblastic leukemia (ALL) in adults. Protocol 1 (18 patients) consisted of an intensive four-drug induction therapy (daunorubicin, cyclophosphamide, vincristine, prednisone), CNS prophylaxis (cranial irradiation and intrathecal methotrexate), and continuous maintenance with methotrexate and mercaptopurine for three years, with periodical reinductions with vincristine and prednisone. Protocol 2 (13 patients) included a similar induction regimen (doxorubicin instead of daunorubicin, dexamethasone instead of prednisone), followed by post-remission intensification with alternating courses of non-cross-resistant agents (amsacrine and high dose cytarabine; vincristine, cyclophosphamide and doxorubicin; etoposide and conventional dose cytarabine) given in a cyclical eight-month program. CNS prophylaxis consisted of intrathecal methotrexate and systemic high-dose cytarabine. The patient characteristics of the two therapy groups were comparable. The complete remission (CR) rate for both groups was 77{\%}, with a median overall and relapse-free survival of 18 and 29 months, respectively. The three-year overall survival of complete remitters was 59{\%}. No correlation was found between CR rate and age, mediastinal, or bone marrow involvement. Stage I disease had a significantly higher CR rate (100{\%}) than did stages II-IV (64{\%}). Leukemic evolution occurred in 32{\%} of cases, within a median time of 11 months from diagnosis; meningeal disease developed in six cases (19{\%}); in four of them leukemia was concomitant. No significant differences were found between the two successive treatments for CR rate, survival, CNS relapses or toxicity. Our overall results, comparable to those of other studies, confirm the efficacy of an ALL-like therapy in adult LBL, irrespective of clinical features, stage or bone marrow involvement at diagnosis.",
author = "C. Bernasconi and E. Brusamolino and M. Lazzarino and E. Morra and G. Pagnucco and E. Orlandi",
year = "1990",
language = "English",
volume = "1",
pages = "141--146",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Lymphoblastic lymphoma in adult patients

T2 - Clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia

AU - Bernasconi, C.

AU - Brusamolino, E.

AU - Lazzarino, M.

AU - Morra, E.

AU - Pagnucco, G.

AU - Orlandi, E.

PY - 1990

Y1 - 1990

N2 - This paper analyzes the clinicopathological features of 31 consecutive adult patients with lymphoblastic lymphoma (LBL) and reports on our experience in treating them with two successive multidrug programs analogous to those used in acute lymphoblastic leukemia (ALL) in adults. Protocol 1 (18 patients) consisted of an intensive four-drug induction therapy (daunorubicin, cyclophosphamide, vincristine, prednisone), CNS prophylaxis (cranial irradiation and intrathecal methotrexate), and continuous maintenance with methotrexate and mercaptopurine for three years, with periodical reinductions with vincristine and prednisone. Protocol 2 (13 patients) included a similar induction regimen (doxorubicin instead of daunorubicin, dexamethasone instead of prednisone), followed by post-remission intensification with alternating courses of non-cross-resistant agents (amsacrine and high dose cytarabine; vincristine, cyclophosphamide and doxorubicin; etoposide and conventional dose cytarabine) given in a cyclical eight-month program. CNS prophylaxis consisted of intrathecal methotrexate and systemic high-dose cytarabine. The patient characteristics of the two therapy groups were comparable. The complete remission (CR) rate for both groups was 77%, with a median overall and relapse-free survival of 18 and 29 months, respectively. The three-year overall survival of complete remitters was 59%. No correlation was found between CR rate and age, mediastinal, or bone marrow involvement. Stage I disease had a significantly higher CR rate (100%) than did stages II-IV (64%). Leukemic evolution occurred in 32% of cases, within a median time of 11 months from diagnosis; meningeal disease developed in six cases (19%); in four of them leukemia was concomitant. No significant differences were found between the two successive treatments for CR rate, survival, CNS relapses or toxicity. Our overall results, comparable to those of other studies, confirm the efficacy of an ALL-like therapy in adult LBL, irrespective of clinical features, stage or bone marrow involvement at diagnosis.

AB - This paper analyzes the clinicopathological features of 31 consecutive adult patients with lymphoblastic lymphoma (LBL) and reports on our experience in treating them with two successive multidrug programs analogous to those used in acute lymphoblastic leukemia (ALL) in adults. Protocol 1 (18 patients) consisted of an intensive four-drug induction therapy (daunorubicin, cyclophosphamide, vincristine, prednisone), CNS prophylaxis (cranial irradiation and intrathecal methotrexate), and continuous maintenance with methotrexate and mercaptopurine for three years, with periodical reinductions with vincristine and prednisone. Protocol 2 (13 patients) included a similar induction regimen (doxorubicin instead of daunorubicin, dexamethasone instead of prednisone), followed by post-remission intensification with alternating courses of non-cross-resistant agents (amsacrine and high dose cytarabine; vincristine, cyclophosphamide and doxorubicin; etoposide and conventional dose cytarabine) given in a cyclical eight-month program. CNS prophylaxis consisted of intrathecal methotrexate and systemic high-dose cytarabine. The patient characteristics of the two therapy groups were comparable. The complete remission (CR) rate for both groups was 77%, with a median overall and relapse-free survival of 18 and 29 months, respectively. The three-year overall survival of complete remitters was 59%. No correlation was found between CR rate and age, mediastinal, or bone marrow involvement. Stage I disease had a significantly higher CR rate (100%) than did stages II-IV (64%). Leukemic evolution occurred in 32% of cases, within a median time of 11 months from diagnosis; meningeal disease developed in six cases (19%); in four of them leukemia was concomitant. No significant differences were found between the two successive treatments for CR rate, survival, CNS relapses or toxicity. Our overall results, comparable to those of other studies, confirm the efficacy of an ALL-like therapy in adult LBL, irrespective of clinical features, stage or bone marrow involvement at diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=0025348654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025348654&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 141

EP - 146

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -